ArticleBreast cancer research : BCR2016
Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas.
Article in Breast cancer research : BCR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis.Scientific reports · 2017Pooled it
- Metabolic reprogramming and functional crosstalk within the tumor microenvironment (TME) and A Multi-omics anticancer approach.Medical oncology (Northwood, London, England) · 2025Review
- Extracellular vesicles, including large translating vesicles called midbody remnants, are released during the cell cycle.Molecular biology of the cell · 2024Article
- Review
- AI-aided holographic flow cytometry for label-free identification of ovarian cancer cells in the presence of unbalanced datasets.APL bioengineering · 2023Article
- Down-regulation of LCN2 attenuates retinal vascular dysfunction and caspase-1-mediated pyroptosis in diabetes mellitus.Annals of translational medicine · 2022Article
- Clinical Applications of Cancer-Associated Cells Present in the Blood of Cancer Patients.Biomedicines · 2022Review
- Challenges and achievements of liquid biopsy technologies employed in early breast cancer.EBioMedicine · 2020Review
- Epithelial-Mesenchymal Transition in Cancer: A Historical Overview.Translational oncology · 2020Review
- Tumor microenvironment complexity and therapeutic implications at a glance.Cell communication and signaling : CCS · 2020Review
- Roles of cell fusion, hybridization and polyploid cell formation in cancer metastasis.World journal of clinical oncology · 2020Review
- Oncogenic Signaling Alters Cell Shape and Mechanics to Facilitate Cell Division under Confinement.Developmental cell · 2020Article
- Mechanosensing of Mechanical Confinement by Mesenchymal-Like Cells.Frontiers in physiology · 2020Review
- Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients.BMC cancer · 2019Article
- Article
- Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer.Cancers · 2019Article
- Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform.PloS one · 2019Article
- Blood-based biopsies-clinical utility beyond circulating tumor cells.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2018Article
- The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues.Journal of visualized experiments : JoVE · 2018Article
- Physical confinement alters sarcoma cell cycle progression and division.Cell cycle (Georgetown, Tex.) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEnumeration of circulating tumor cells (CTCs) isolated from the peripheral blood of breast cancer patients holds promise as a clinically relevant, minimally invasive diagnostic test. However, CTC utility has been limited as a prognostic indicator of survival by the inability to stratify patients beyond general enumeration. In comparison, histological biopsy examinations remain the standard method for confirming malignancy and grading malignant cells, allowing for cancer identification and then assessing patient cohorts for prognostic and predictive value. Typically, CTC identification relies on immunofluorescent staining assessed as absent/present, which is somewhat subjective and limited in its ability to characterize these cells. In contrast, the physical features used in histological cytology comprise the gold standard method used to identify and preliminarily characterize the cancer cells. Here, we superimpose the methods, cytologically subtyping CTCs labeled with immunohistochemical fluorescence stains to improve their prognostic value in relation to survival.
methodsIn this single-blind prospective pilot study, we tracked 36 patients with late-stage breast cancer over 24 months to compare overall survival between simple CTC enumeration and subtyping mitotic CTCs. A power analysis (1-β = 0. 9, α = 0.05) determined that a pilot size of 30 patients was sufficient to stratify this patient cohort; 36 in total were enrolled.
resultsOur results confirmed that CTC number is a prognostic indicator of patient survival, with a hazard ratio 5.2, p = 0.005 (95 % CI 1.6-16.5). However, by simply subtyping the same population based on CTCs in cytological mitosis, the hazard ratio increased dramatically to 11.1, p < 0.001 (95 % CI 3.1-39.7).
conclusionsOur data suggest that (1) mitotic CTCs are relativity common in aggressive late-stage breast cancer, (2) mitotic CTCs may significantly correlate with shortened overall survival, and (3) larger and more defined patient cohort studies are clearly called for based on this initial pilot study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.